Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials
Identifieur interne : 000065 ( Istex/Curation ); précédent : 000064; suivant : 000066Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials
Auteurs : Cristina Sampaio [Portugal] ; Juliana Bronzova [Pays-Bas] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Serge V. Van De Witte [Pays-Bas] ; And Ad Theeuwes [Pays-Bas]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-07.
English descriptors
- KwdEn :
Abstract
This report presents the results of 2 randomized trials—Rembrandt and Vermeer—on the efficacy and safety of pardoprunox in patients with early Parkinson's disease. Patients with Parkinson's disease with a Unified Parkinson's Disease Rating Scale–Motor score ≥ 10 and modified Hoehn and Yahr stage ≤ 3 were randomized to pardoprunox (fixed doses of 6 mg/day [n = 115] or 12 mg/day [n = 118] or a flexible‐dose range of 12–42 mg/day [n = 116]) or placebo (n = 119) in Rembrandt and pardoprunox 12–42 mg/day (n = 108), pramipexole 1.5–4.5 mg/day (n = 116), or placebo (n = 110) in Vermeer. Pardoprunox showed a significant benefit over placebo in the primary efficacy variable, least‐square mean change from baseline in Unified Parkinson's Disease Rating Scale–Motor score: Rembrandt—fixed doses of 6 and 12 mg/day, −6.0 and −4.7 points, respectively; flexible‐dose 12–42 mg/day, −5.5 points; placebo, −2.9 points; Vermeer—flexible‐dose 12–42 mg/day, −4.9 points; placebo, −2.5 points; pramipexole, −5.7 points. No minimum effective dose was established. Secondary efficacy parameters supported the results of the primary efficacy variable. Pardoprunox tolerability was dose related: flexible‐dose 12–42 mg/day showed the highest dropout rate due to treatment‐emergent adverse events (Rembrandt, 56.0%; Vermeer, 46.3%) and overall incidence of treatment‐emergent adverse events (Rembrandt, 97.4%; Vermeer, 92.6%), primarily due to nausea, somnolence, and dizziness. Because pardoprunox showed similar efficacy across all dose groups, these observations suggest that the 12–42 mg/day dose range was higher than therapeutically required. Furthermore, the early onset of treatment‐emergent adverse events and dropouts observed for pardoprunox suggest that titration was too rapid. Pardoprunox significantly improved motor symptoms in patients with early Parkinson's disease, but further investigation into the dose and titration schedule is required to improve tolerability. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23590
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000065
Links to Exploration step
ISTEX:5F1B5BA930CAA821B9BFB5C07BFE579A366E4094Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials</title>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation wicri:level="1"><mods:affiliation>Laboratório de Farmacologia Clinica e Terapêutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Edifício do Hospital de Santa Maria, Lisboa, Portugal</mods:affiliation>
<country xml:lang="fr">Portugal</country>
<wicri:regionArea>Laboratório de Farmacologia Clinica e Terapêutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Edifício do Hospital de Santa Maria, Lisboa</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bronzova, Juliana" sort="Bronzova, Juliana" uniqKey="Bronzova J" first="Juliana" last="Bronzova">Juliana Bronzova</name>
<affiliation wicri:level="1"><mods:affiliation>Solvay Pharmaceuticals B.V., (Solvay is now Abbott), Weesp, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Solvay Pharmaceuticals B.V., (Solvay is now Abbott), Weesp</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="1"><mods:affiliation>University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><mods:affiliation>Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Hospital, University of Toronto, Toronto, Ontario</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Faculty of Medicine, University Hospital of Toulouse, Toulouse, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Clinical Pharmacology, Faculty of Medicine, University Hospital of Toulouse, Toulouse</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Van De Witte, Serge V" sort="Van De Witte, Serge V" uniqKey="Van De Witte S" first="Serge V." last="Van De Witte">Serge V. Van De Witte</name>
<affiliation wicri:level="1"><mods:affiliation>Solvay Pharmaceuticals B.V., (Solvay is now Abbott), Weesp, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Solvay Pharmaceuticals B.V., (Solvay is now Abbott), Weesp</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Theeuwes, And Ad" sort="Theeuwes, And Ad" uniqKey="Theeuwes A" first="And Ad" last="Theeuwes">And Ad Theeuwes</name>
<affiliation wicri:level="1"><mods:affiliation>Solvay Pharmaceuticals B.V., (Solvay is now Abbott), Weesp, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Solvay Pharmaceuticals B.V., (Solvay is now Abbott), Weesp</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:5F1B5BA930CAA821B9BFB5C07BFE579A366E4094</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1002/mds.23590</idno>
<idno type="url">https://api.istex.fr/document/5F1B5BA930CAA821B9BFB5C07BFE579A366E4094/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000065</idno>
<idno type="wicri:Area/Istex/Curation">000065</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials</title>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation wicri:level="1"><mods:affiliation>Laboratório de Farmacologia Clinica e Terapêutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Edifício do Hospital de Santa Maria, Lisboa, Portugal</mods:affiliation>
<country xml:lang="fr">Portugal</country>
<wicri:regionArea>Laboratório de Farmacologia Clinica e Terapêutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Edifício do Hospital de Santa Maria, Lisboa</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bronzova, Juliana" sort="Bronzova, Juliana" uniqKey="Bronzova J" first="Juliana" last="Bronzova">Juliana Bronzova</name>
<affiliation wicri:level="1"><mods:affiliation>Solvay Pharmaceuticals B.V., (Solvay is now Abbott), Weesp, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Solvay Pharmaceuticals B.V., (Solvay is now Abbott), Weesp</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="1"><mods:affiliation>University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><mods:affiliation>Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Hospital, University of Toronto, Toronto, Ontario</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Faculty of Medicine, University Hospital of Toulouse, Toulouse, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Clinical Pharmacology, Faculty of Medicine, University Hospital of Toulouse, Toulouse</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Van De Witte, Serge V" sort="Van De Witte, Serge V" uniqKey="Van De Witte S" first="Serge V." last="Van De Witte">Serge V. Van De Witte</name>
<affiliation wicri:level="1"><mods:affiliation>Solvay Pharmaceuticals B.V., (Solvay is now Abbott), Weesp, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Solvay Pharmaceuticals B.V., (Solvay is now Abbott), Weesp</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Theeuwes, And Ad" sort="Theeuwes, And Ad" uniqKey="Theeuwes A" first="And Ad" last="Theeuwes">And Ad Theeuwes</name>
<affiliation wicri:level="1"><mods:affiliation>Solvay Pharmaceuticals B.V., (Solvay is now Abbott), Weesp, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Solvay Pharmaceuticals B.V., (Solvay is now Abbott), Weesp</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2011-07">2011-07</date>
<biblScope unit="vol">26</biblScope>
<biblScope unit="issue">8</biblScope>
<biblScope unit="page" from="1464">1464</biblScope>
<biblScope unit="page" to="1476">1476</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">5F1B5BA930CAA821B9BFB5C07BFE579A366E4094</idno>
<idno type="DOI">10.1002/mds.23590</idno>
<idno type="ArticleID">MDS23590</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term>
<term>pardoprunox (SLV308)</term>
<term>partial dopamine agonist</term>
<term>randomized controlled trial</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This report presents the results of 2 randomized trials—Rembrandt and Vermeer—on the efficacy and safety of pardoprunox in patients with early Parkinson's disease. Patients with Parkinson's disease with a Unified Parkinson's Disease Rating Scale–Motor score ≥ 10 and modified Hoehn and Yahr stage ≤ 3 were randomized to pardoprunox (fixed doses of 6 mg/day [n = 115] or 12 mg/day [n = 118] or a flexible‐dose range of 12–42 mg/day [n = 116]) or placebo (n = 119) in Rembrandt and pardoprunox 12–42 mg/day (n = 108), pramipexole 1.5–4.5 mg/day (n = 116), or placebo (n = 110) in Vermeer. Pardoprunox showed a significant benefit over placebo in the primary efficacy variable, least‐square mean change from baseline in Unified Parkinson's Disease Rating Scale–Motor score: Rembrandt—fixed doses of 6 and 12 mg/day, −6.0 and −4.7 points, respectively; flexible‐dose 12–42 mg/day, −5.5 points; placebo, −2.9 points; Vermeer—flexible‐dose 12–42 mg/day, −4.9 points; placebo, −2.5 points; pramipexole, −5.7 points. No minimum effective dose was established. Secondary efficacy parameters supported the results of the primary efficacy variable. Pardoprunox tolerability was dose related: flexible‐dose 12–42 mg/day showed the highest dropout rate due to treatment‐emergent adverse events (Rembrandt, 56.0%; Vermeer, 46.3%) and overall incidence of treatment‐emergent adverse events (Rembrandt, 97.4%; Vermeer, 92.6%), primarily due to nausea, somnolence, and dizziness. Because pardoprunox showed similar efficacy across all dose groups, these observations suggest that the 12–42 mg/day dose range was higher than therapeutically required. Furthermore, the early onset of treatment‐emergent adverse events and dropouts observed for pardoprunox suggest that titration was too rapid. Pardoprunox significantly improved motor symptoms in patients with early Parkinson's disease, but further investigation into the dose and titration schedule is required to improve tolerability. © 2011 Movement Disorder Society</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000065 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000065 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Istex |étape= Curation |type= RBID |clé= ISTEX:5F1B5BA930CAA821B9BFB5C07BFE579A366E4094 |texte= Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials }}
This area was generated with Dilib version V0.6.23. |